1. Home
  2. USA vs VIR Comparison

USA vs VIR Comparison

Compare USA & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty All-Star Equity Fund

USA

Liberty All-Star Equity Fund

HOLD

Current Price

$5.96

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$9.51

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USA
VIR
Founded
N/A
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
USA
VIR
Price
$5.96
$9.51
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$19.43
AVG Volume (30 Days)
1.7M
2.3M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.49
EPS
N/A
N/A
Revenue
N/A
$68,556,000.00
Revenue This Year
N/A
$270.22
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.40
$4.16
52 Week High
$6.86
$11.66

Technical Indicators

Market Signals
Indicator
USA
VIR
Relative Strength Index (RSI) 64.66 47.38
Support Level $5.93 $8.40
Resistance Level $6.00 $10.25
Average True Range (ATR) 0.06 0.47
MACD 0.02 -0.04
Stochastic Oscillator 90.54 3.60

Price Performance

Historical Comparison
USA
VIR

About USA Liberty All-Star Equity Fund

Liberty All Star Equity Fund is a diversified, closed-end management investment company. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Share on Social Networks: